Evaluation of Safety and Effectiveness of the SONICO-CX Intracoronary Electrohydraulic Shockwave Balloon Catheter
NCT ID: NCT05732025
Last Updated: 2023-02-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
12 participants
INTERVENTIONAL
2023-05-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
ShOckwave ballooN or Atherectomy With Rotablation in Calcified Coronary Artery Lesions, the SONAR Trial
NCT05208749
Rotablation vs Intravascular Lithotripsy in Calcified Coronary Lesions
NCT04960319
Comparison of RA-IVL and RA-SHP in Calcified Coronary Lesions
NCT07279987
IVL and RA in Treatment of Balloon-crossable Severely Calcified Coronary Lesions
NCT04556682
Shockwave IVL + DCB
NCT05625997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Electrohydraulic shock wave lithotripsy
Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
Electrohydraulic shock wave lithotripsy
Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
Rotary atherectomy
Pre-treatment of severe calcified coronary lesions with Rotary atherectomy
Rotary atherectomy
Pre-treatment of severe calcified coronary lesions with rotary atherectomy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electrohydraulic shock wave lithotripsy
Pre-treatment of severe calcified coronary lesions with electrohydraulic shock wave lithotripsy
Rotary atherectomy
Pre-treatment of severe calcified coronary lesions with rotary atherectomy
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Age ≥ 18 years old
2. Evidence of asymptomatic ischemia, stable or unstable angina
3. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent, and are willing to accept angiography, OCT examination and clinical follow-up.
* Angiographic Criteria:
1. The target lesion is primary and in situ coronary artery lesion
2. The length of the target lesion is ≤60mm, and the diameter of the target lesion is 2.5-4.0mm (visually)
3. The stenosis rate of the target lesion diameter is ≥70%, and the doctor judges that it is necessary to implant a stent (visual inspection method) to meet one of the following:
1. Diameter stenosis ≥ 70%, \< 100%
2. ≥50%, \<70% with evidence of ischemia
4. The lesion allows a 0.014 guidewire to pass
5. Under multi-angle imaging conditions, calcified shadow lesions can be seen on both sides of the lesion vessel wall (the target lesion meets the definition of severe calcification)
Exclusion Criteria
1. Acute myocardial infarction occurred within 30 days before operation
2. Use special balloons (chocolate balloons, scored balloons, spinous balloons, etc.) to treat lesions at the same time
3. Troponin is greater than 5 times the upper limit of laboratory normal value within one week before operation
4. Severe cardiac dysfunction (grade III or IV)
5. Left ventricular ejection fraction \<25%
6. The patient refuses emergency CABG surgery or does not have indications for emergency CABG surgery
7. Severe uncontrolled hypertension (systolic blood pressure \>180 mm Hg or diastolic blood pressure \>110 mm Hg)
8. Severe renal failure (serum creatinine \> 221 μmol/L)
9. Preoperative hemoglobin \<100g/L
10. Obvious coagulation dysfunction (platelet count\<100×109/L or INR\>1.7, INR is only required for patients who have taken warfarin orally within 2 weeks before enrollment)
11. Blood hypercoagulability diseases (such as polycythemia vera, platelet count \>750×109/L, etc.)
12. History of stroke or TIA within 3 months
13. History of active peptic ulcer or upper gastrointestinal bleeding within 6 months
14. The life expectancy of the patient is less than 12 months
15. The patient has an active systemic infection
16. The patient has a connective tissue disorder (such as Marfan syndrome)
17. Patient is allergic to contrast material
18. Patients undergoing heart transplantation
19. Patients with implanted cardiac pacemakers
20. The patient is pregnant or breastfeeding
21. Those who have participated in clinical trials of other drugs or medical devices within one month before enrollment;
22. Other circumstances that the investigator considers inappropriate to participate in the trial
* Angiographic Criteria:
1. Unprotected left main lesion (left main visual stenosis \>50%)
2. Baseline TIMI blood flow is less than grade 3 (evaluation after pre-dilation is allowed)
3. A stent has been implanted within 10mm of the proximal or distal end of the target lesion
4. The target lesion is located distal to the saphenous vein or LIMA/RIMA bypass graft
5. Aneurysm in the target vessel
6. Angiography confirmed the presence of thrombus in the target vessel
7. Chronic total occlusive disease
8. Angiography confirmed the presence of severe dissection of the target lesion before hydroelectric shock wave lithotripsy (D-F type dissection (NHLBI classification)
9. The investigator judged that the target lesion is not suitable for patients with vasodilation
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Second Affiliated Hospital, School of Medicine, Zhejiang University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jian-an Wang, MD,PhD
Role: PRINCIPAL_INVESTIGATOR
Second Affiliated Hospital of Zhejiang University, School of Medicine
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAHZJU CT020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.